Stockreport

Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease enter [Read more]